Page 1

COMPASSION Navigating Mental Health Pathways COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021 November 9 , 2021 Highlights : • Positive topline results from phase Ilb COMP360 psilocybin therapy trial for treatment - resistant depression ; rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological support • Launch of phase II study of COMP360 psilocybin therapy for PTSD • Positive signals from Maryland Oncology Hematology open - label investigator initiated study of COMP360 psilocybin therapy for depression in cancer • Acquisition of IP portfolio of novel psychedelic compounds and prodrugs • Hamilton Morris appointed full - time consultant • New US composition patent granted for crystalline psilocybin • Conference call today at 1:00 pm UK ( 8:00 am ET ) LONDON , Nov. 09 , 2021 ( GLOBE NEWSWIRE ) -- COMPASS Pathways plc ( Nasdaq : CMPS ) ( " COMPASS " ) , a mental health care company dedicated to accelerating patient access to evidence - based innovation in mental health , today reported its financial results for the third quarter 2021 and gave an update on recent progress across its business . George Goldsmith , Chairman , CEO and Co - founder , COMPASS Pathways , said , " With the positive topline results from our COMP360 psilocybin therapy phase IIb trial , we are one step closer to potentially providing a much - needed therapeutic option to patients suffering with treatment - resistant depression . At the same time , we are making great progress in broadening our pipeline - we are beginning a phase II COMP360 psilocybin therapy trial for PTSD , and we have acquired a large portfolio of new compounds and IP , working with Matthias Grill PhD . Our goal remains the same - to transform mental health care and bring options to the millions of patients who currently don't have many . " Business highlights • Positive topline results from groundbreaking phase IIb clinical trial of COMP360 psilocybin therapy for treatment - resistant depression ( TRD ) ; data shared in separate press release published today • Continued investment in the expansion of COMPASS portfolio with addition of phase II trial of COMP360 psilocybin therapy in post - traumatic stress disorder ( PTSD ) o 20 patient , fixed dose , open - label trial to begin at The Institute of Psychiatry , Psychology & Neuroscience ( loPPN ) King's College London • Promising data from open - label investigator - initiated study of COMP360 psilocybin therapy for depression in cancer , conducted and reported by Maryland Oncology Hematology at the Aquilino Cancer Center ( Rockville , MD ) o Showed feasibility of simultaneous psilocybin administration in small groups , with 1 : 1 support o Remission in major depression symptoms for 15 of the 30 patients , sustained for eight - week follow - up • COMP360 psilocybin found to be generally well - tolerated with no treatment - related serious adverse events • Acquisition of intellectual property ( IP ) portfolio including patent applications covering a variety of psychedelic and empathogenic substances o IP developed with Dr Matthias Grill , founder and CEO of MIHKAL GmbH in Basel , Switzerland o Working with Dr Grill on exclusive research project to develop new product candidates • Hamilton Morris , research scientist and filmmaker , appointed full - time consultant o Researching new psychedelic compounds that could be developed into therapies in areas of unmet mental health need • New US patent granted o Claims covering alternative crystalline psilocybin not used in COMP360 o Portfolio of nine granted patents , including four in the US , two in the UK , one in Germany , two in Hong Kong Financial highlights • Net loss for the three months ended 30 September 2021 was $ 15.8 million or $ 0.38 loss per share ( after including non - cash share - based compensation expense of $ 2.3 million ) , compared with $ 16.7 million or $ 1.30 loss per share during the same period in 2020 ( after including non - cash - share - based compensation expense of $ 5.2 million ) .